(News Bulletin 247) – RBC reaffirms its ‘performance in line with the sector’ recommendation and its price target of 120 euros on Ipsen, after the presentation of positive phase III data concerning its Cabometyx in stage-stage prostate cancer advance.
While full data is still required to assess its potential, RBC believes ‘strong data could support a significant boost to sales of Cabometyx, currently driven by its use in the context of kidney cancer’.
‘In the meantime, Cabometyx will remain an important growth driver for Ipsen, particularly in front-line kidney cancer’, judge RBC, which anticipates sales of 546 million euros this year (+ 22%), then a peak of 786 million by 2028.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
